Contineum Therapeutics (CTNM) Liabilities and Shareholders Equity: 2023-2025
Historic Liabilities and Shareholders Equity for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $190.8 million.
- Contineum Therapeutics' Liabilities and Shareholders Equity fell 11.66% to $190.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $784.8 million, marking a year-over-year increase of 13.53%. This contributed to the annual value of $212.8 million for FY2024, which is 63.24% up from last year.
- Per Contineum Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $190.8 million for Q3 2025, which was up 4.35% from $182.9 million recorded in Q2 2025.
- In the past 5 years, Contineum Therapeutics' Liabilities and Shareholders Equity registered a high of $221.4 million during Q2 2024, and its lowest value of $123.6 million during Q1 2024.
- Over the past 3 years, Contineum Therapeutics' median Liabilities and Shareholders Equity value was $194.6 million (recorded in 2025), while the average stood at $184.5 million.
- Per our database at Business Quant, Contineum Therapeutics' Liabilities and Shareholders Equity surged by 63.24% in 2024 and then fell by 17.38% in 2025.
- Quarterly analysis of 3 years shows Contineum Therapeutics' Liabilities and Shareholders Equity stood at $130.4 million in 2023, then spiked by 63.24% to $212.8 million in 2024, then decreased by 11.66% to $190.8 million in 2025.
- Its Liabilities and Shareholders Equity stands at $190.8 million for Q3 2025, versus $182.9 million for Q2 2025 and $198.3 million for Q1 2025.